Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA RAE BURGY

Allopathic & Osteopathic Physicians Dermatology

NPI
1275826521
CMS profile
1388571
Location
COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,775.38

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,758.48 170
Education $16.90 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA RAE BURGY

NPI 1275826521 · CMS profile ID 1388571

Allopathic & Osteopathic Physicians / Dermatology

COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275826521?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA RAE BURGY, NPI 1275826521, CMS profile ID 1388571. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275826521?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JESSICA RAE BURGY, NPI 1275826521, CMS profile ID 1388571. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275826521?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JESSICA RAE BURGY, NPI 1275826521, CMS profile ID 1388571, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1275826521?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $2,775.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $24.9109/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050485863 CMS
AbbVie Inc. $23.2209/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996333209 CMS
E.R. Squibb & Sons, L.L.C. $23.6309/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630333 CMS
GENZYME CORPORATION $11.6509/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050220943 CMS
UCB, Inc. $19.0009/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021530299 CMS
AbbVie Inc. $8.4508/31/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996333205 CMS
AbbVie Inc. $8.4508/31/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996333207 CMS
Dermavant Sciences, Inc. $19.2708/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991164475 CMS
E.R. Squibb & Sons, L.L.C. $7.7508/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630341 CMS
E.R. Squibb & Sons, L.L.C. $1.0508/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630345 CMS
PFIZER INC. $22.3608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050502689 CMS
Janssen Biotech, Inc. $5.6708/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988347177 CMS
E.R. Squibb & Sons, L.L.C. $3.7308/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630317 CMS
E.R. Squibb & Sons, L.L.C. $0.4108/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630321 CMS
Janssen Biotech, Inc. $20.3508/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988347239 CMS
Novartis Pharmaceuticals Corporation $2.6608/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991476445 CMS
Regeneron Healthcare Solutions, Inc. $6.8108/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999108601 CMS
AbbVie Inc. $6.5408/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996333203 CMS
AbbVie Inc. $13.9408/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996333201 CMS
Novartis Pharmaceuticals Corporation $24.6208/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991476389 CMS
Regeneron Healthcare Solutions, Inc. $11.2208/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999108597 CMS
Regeneron Healthcare Solutions, Inc. $6.9008/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999108593 CMS
Lilly USA, LLC $20.1008/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031626419 CMS
GENZYME CORPORATION $12.8008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050220935 CMS
PFIZER INC. $25.6408/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050591501 CMS
Incyte Corporation $27.0308/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044293439 CMS
UCB, Inc. $15.5908/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021530287 CMS
Amgen Inc. $6.9708/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020600739 CMS
E.R. Squibb & Sons, L.L.C. $7.0408/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630313 CMS
LEO Pharma Inc. $24.9008/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053458581 CMS
Regeneron Healthcare Solutions, Inc. $25.4708/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999108589 CMS
Sun Pharmaceutical Industries Inc. $20.7507/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053871669 CMS
AbbVie Inc. $9.0007/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996333199 CMS
AbbVie Inc. $13.2207/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996333197 CMS
Novartis Pharmaceuticals Corporation $5.1107/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991476437 CMS
GENZYME CORPORATION $10.9007/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050220929 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.5407/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051612311 CMS
Arcutis Biotherapeutics, Inc. $14.0307/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044745188 CMS
E.R. Squibb & Sons, L.L.C. $5.9107/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630305 CMS
E.R. Squibb & Sons, L.L.C. $6.9107/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630301 CMS
AbbVie Inc. $15.5107/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996333195 CMS
UCB, Inc. $20.4907/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021530303 CMS
E.R. Squibb & Sons, L.L.C. $21.1406/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630281 CMS
Regeneron Healthcare Solutions, Inc. $4.8006/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999108585 CMS
PFIZER INC. $17.3606/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049552143 CMS
Lilly USA, LLC $23.2006/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031676145 CMS
GENZYME CORPORATION $5.8306/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050220925 CMS
Amgen Inc. $26.4006/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020600737 CMS
Regeneron Healthcare Solutions, Inc. $38.5706/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999108581 CMS
E.R. Squibb & Sons, L.L.C. $7.4106/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015630265 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $883.64 57
PY2020 $1,143.63 62
PY2021 $1,433.55 89
PY2022 $1,535.61 93
PY2023 $2,775.38 172
PY2024 $3,132.39 175
PY2025 $3,517.75 226

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $291,085.40 26
PY2024 Recipient $1,717.54 9
PY2024 Principal investigator $209,734.74 18
PY2023 Recipient $18,892.00 1
PY2023 Principal investigator $4,205.52 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $4,270.00 12/15/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146525
Principal investigator 1 PFIZER INC. $1,109.55 12/03/2025 Non-covered Recipient Entity
Columbia Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228744992
Principal investigator 1 PFIZER INC. $1,109.55 11/26/2025 Non-covered Recipient Entity
Columbia Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228737497
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,500.00 11/20/2025 Non-covered Recipient Entity
Columbia Dermatology and Aesthetics
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431268
Principal investigator 1 SANOFI US SERVICES INC. $6,602.00 11/17/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146514
Principal investigator 1 PFIZER INC. $1,364.35 10/29/2025 Non-covered Recipient Entity
Columbia Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228741417
Principal investigator 1 SANOFI US SERVICES INC. $4,505.00 09/22/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146475
Principal investigator 1 PFIZER INC. $3,824.60 09/12/2025 Non-covered Recipient Entity
Columbia Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228759709
Principal investigator 1 SANOFI US SERVICES INC. $3,466.00 08/18/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146471
Principal investigator 1 SANOFI US SERVICES INC. $3,136.00 07/14/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146466
Principal investigator 1 Eli Lilly and Company $7,540.00 07/01/2025 Non-covered Recipient Entity
COLUMBIA DERMATOLOGY
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187878795
Principal investigator 1 SANOFI US SERVICES INC. $4,284.00 06/16/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146463
Principal investigator 1 SANOFI US SERVICES INC. $11,601.00 06/09/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146454
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 06/09/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146458
Principal investigator 1 PFIZER INC. $2,408.25 05/16/2025 Non-covered Recipient Entity
Jessica Burgy
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772805
Principal investigator 1 SANOFI US SERVICES INC. $4,615.00 04/28/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146450
Principal investigator 1 PFIZER INC. $2,485.20 04/09/2025 Non-covered Recipient Entity
Jessica Burgy
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781449
Principal investigator 1 Eli Lilly and Company $15,025.00 04/01/2025 Non-covered Recipient Entity
COLUMBIA DERMATOLOGY
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187876611
Principal investigator 1 Eli Lilly and Company $1,084.80 03/25/2025 Non-covered Recipient Entity
COLUMBIA DERMATOLOGY
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187878793
Principal investigator 1 SANOFI US SERVICES INC. $3,662.00 03/17/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146441
Principal investigator 1 PFIZER INC. $1,277.25 03/04/2025 Non-covered Recipient Entity
Jessica Burgy
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228787335
Principal investigator 1 SANOFI US SERVICES INC. $4,020.00 02/18/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146435
Principal investigator 1 PFIZER INC. $2,408.25 02/11/2025 Non-covered Recipient Entity
Jessica Burgy
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228751846
Principal investigator 1 SANOFI US SERVICES INC. $4,361.00 01/21/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146437
Principal investigator 1 SANOFI US SERVICES INC. $975.60 01/13/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146430
Principal investigator 1 Eli Lilly and Company $175,151.00 01/08/2025 Non-covered Recipient Entity
COLUMBIA DERMATOLOGY
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187879649